Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis
Authors
Keywords
Chronic migraine, Systematic literature review, Network meta-analysis, Anti-CGRP mAbs
Journal
CLINICAL NEUROLOGY AND NEUROSURGERY
Volume 209, Issue -, Pages 106893
Publisher
Elsevier BV
Online
2021-08-14
DOI
10.1016/j.clineuro.2021.106893
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
- (2020) Hong Deng et al. BMC Neurology
- A new generation of headache drugs
- (2020) Marcus Woo NATURE
- CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis
- (2019) Lin Han et al. Brain and Behavior
- Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials
- (2019) Da Xu et al. CEPHALALGIA
- Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials
- (2019) I-Hsin Huang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
- (2019) Robert Croop et al. LANCET
- Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study
- (2019) Richard B. Lipton et al. HEADACHE
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine
- (2019) Richard B. Lipton et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis
- (2018) Yuhan Zhu et al. NEUROLOGICAL SCIENCES
- A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
- (2018) Angelo Camporeale et al. BMC Neurology
- Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
- (2018) Janet H Ford et al. Patient Preference and Adherence
- The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
- (2017) Min Hou et al. JOURNAL OF HEADACHE AND PAIN
- Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants
- (2017) Yohannes W. Woldeamanuel et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2017) Theo Vos et al. LANCET
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2017) Valery L Feigin et al. LANCET NEUROLOGY
- Pathophysiology of Migraine: A Disorder of Sensory Processing
- (2017) Peter J. Goadsby et al. PHYSIOLOGICAL REVIEWS
- A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
- (2016) Tiffini Voss et al. CEPHALALGIA
- Network meta-analysis of migraine disorder treatment by NSAIDs and triptans
- (2016) Haiyang Xu et al. JOURNAL OF HEADACHE AND PAIN
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine
- (2015) Andrew F. Russo Annual Review of Pharmacology and Toxicology
- Therapeutic antibodies against CGRP or its receptor
- (2015) Marcelo E. Bigal et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
- (2014) M. A. Puhan et al. BMJ-British Medical Journal
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
- (2013) Ronald Marcus et al. CEPHALALGIA
- Graphical Tools for Network Meta-Analysis in STATA
- (2013) Anna Chaimani et al. PLoS One
- Evidence Synthesis for Decision Making 2
- (2012) Sofia Dias et al. MEDICAL DECISION MAKING
- Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
- (2011) David J Hewitt et al. CEPHALALGIA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started